Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18394388 | 0.83 | CYP17A1 (0.35) | CYP17A1CYP1A2TRPA1HSD11B1MALT1 | |
| SCHEMBL12528560 | 0.83 | HSD11B1 (0.42) | CYP17A1CYP1A2HSD11B1HDAC9 | |
| SCHEMBL950266 | 0.83 | ALDH1A1 (0.44) | CYP17A1CYP1A2TRPA1HSD11B1 | |
| SCHEMBL30427243 | 0.80 | PDE10A (0.45) | CYP17A1CYP1A2 | |
| SCHEMBL12482583 | 0.76 | CYP17A1 (0.55) | CYP17A1CYP1A2GRM4 | |
| SCHEMBL18075005 | 0.76 | CYP1A2 (0.35) | CYP1A2SMN1; SMN2 | |
| SCHEMBL952863 | 0.74 | NOTUM (0.48) | MALT1 | |
| SCHEMBL17219927 | 0.73 | ELANE (0.42) | PLAUELANECYP1A2SMN1; SMN2 | |
| SCHEMBL15671484 | 0.73 | EGLN1 (0.57) | SMN1; SMN2GRM4 | |
| SCHEMBL6271350 | 0.72 | BCHE (0.46) | PLAUELANESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |